SOUTH EASTON, Mass, Aug. 26, 2015 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced it has entered into a two-year collaboration with the Institute of Bioinformatics ("IOB") in Bangalore, India. The IOB is one of the most prestigious not-for-profit scientific research centers in India, and one of the more highly regarded proteomic research organizations worldwide. The IOB staff, which includes dozens of scientists with advanced degrees, have published several hundred scientific papers over the past decade, many with a strong focus in the areas of proteomics, genomics, and metabolomics.
The Founder and Director of the IOB is Akhilesh Pandey M.D., Ph.D. Currently, Dr. Pandey is a Professor at the Institute of Genetic Medicine and the Departments of Biological Chemistry, Oncology, and Pathology at the Johns Hopkins School of Medicine. Dr. Pandey has received numerous prestigious honors and awards during his career, including, most recently, the Era of Hope Scholar Award by the United States Department of Defense. This award is "intended for exceptionally talented, early-career scientists who have demonstrated that they are the best and the brightest in their field(s) through extraordinary creativity, vision, and productivity, and who have shown a strong potential for leadership in the breast cancer community as well as a vision for the eradication of breast cancer."
Dr. Pandey commented: "The preparation of samples for analysis is a crucial step in all research studies worldwide aimed at finding biomarkers for the detection, control, prevention, and/or cure of human diseases and disorders. The IOB has modern, well-equipped facilities; however, we are well aware that the quality of results from our state-of-the-art instruments depends to a great extent on the quality and uniformity of the preparation of the samples being analyzed. Consequently, we are always searching for better, higher quality sample preparation methods that can help us process a diverse set of samples ranging from tissue biopsies to bacterial extracts. This is how we met our colleagues at PBI, learned about the power of their PCT platform, and subsequently purchased our first PCT instrument."
Dr. Harsha Gowda, head of the proteomics program at the IOB, said: "For much of the past year, we have evaluated the PCT platform in our laboratories. We have used it extensively for preparing protein samples from paraffin-embedded biopsy tissue sections for mass spectrometry-based analysis. Early results from this very robust platform are encouraging and exciting. Consequently, we were pleased to enter into a formal, two-year collaboration with our colleagues at PBI. During this time, we will use the PCT platform as the front-end, sample preparation method to many universally-used analytical instruments, such as mass spectrometers and third generation DNA sequencers. Based on our results to date, we believe the PCT platform may prove to be advantageous as a sample preparation method to researchers worldwide, and perhaps also necessary for many other applications as well."
Mr. Richard T. Schumacher, President and CEO of PBI, said: "We are honored to work with such a worldwide respected scientist as Dr. Pandey. We are further honored to collaborate with Dr. Gowda and his colleagues at the IOB. We believe there are as many as 500,000 researchers around the world working with biological samples, many of whom use the same kinds of instruments (e.g., mass spectrometers, DNA sequencers, HPLCs, etc.) as those used by scientists at the IOB. These researchers are potential future users of the PCT platform. We believe the results generated at the IOB will help show the clear advantages offered by the PCT platform when this powerful, patented technology is used in the search for biomarkers. We believe that such data, coming from a research institute with the worldwide reputation of the IOB, could have the profound effect of helping to change the PCT platform from a "want to have" to a "have to have" sample preparation system for biological research laboratories, in India and around the world."
About the Institute of Bioinformatics
The Institute of Bioinformatics is a not-for-profit research organization engaged in biomedical research. Located in Bangalore, India, it was established in May 2002. Bangalore is a prime center for research and development and is the hub of both information technology and biotechnology in India. The Institute of Bioinformatics is a multidisciplinary systems biology research institute where scientists combine cutting-edge experimental methods in genomics, proteomics, and metabolomics with advanced computational biology, to investigate biomarkers and therapeutic targets of various diseases, including cancer.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter
Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
Nathan P. Lawrence, Ph.D. VP of Marketing and Sales
+1(508) 230-1828 (T)
SOURCE Pressure BioSciences, Inc.